Soligenix’s RiVax vaccine shows non-human primate protection vs. ricin toxin

Soligenix announced publication of preclinical immunogenicity challenge studies for RiVax – heat stable ricin toxin vaccine – demonstrating statistically significant correlates of protection predicting survival after lethal aerosolized ricin challenge in non-human primates – NHPs -. This same thermostabilization approach is also being advanced in the development of Soligenix’s CiVax vaccine for COVID-19 and SuVax and MarVax vaccines for ebola type filovirus infections. RiVax is the company’s vaccine candidate for the prevention of death following exposure to a lethal dose of ricin toxin using a unique antigen that is completely devoid of the toxic activity of ricin. These results, coupled with the recent demonstration of statistically significant correlates of protection via the EPICC assay, position RiVax for additional clinical and pivotal non-clinical studies under the FDA Animal Rule.